Title : Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.

Pub. Date : 2012 Aug

PMID : 22665525






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The topoisomerase I inhibitor irinotecan is used to treat advanced colorectal cancer and has been shown to have p53-independent anticancer activity. Irinotecan tumor protein p53 Homo sapiens
2 The aim of this study was to identify the p53-independent signaling mechanisms activated by irinotecan. Irinotecan tumor protein p53 Homo sapiens
3 Transcriptional profiling of isogenic HCT116 p53 wild-type and p53 null cells was carried out following treatment with the active metabolite of irinotecan, SN38. Irinotecan tumor protein p53 Homo sapiens
4 Transcriptional profiling of isogenic HCT116 p53 wild-type and p53 null cells was carried out following treatment with the active metabolite of irinotecan, SN38. Irinotecan tumor protein p53 Homo sapiens